Gilead Sciences (GILD) Construction in Progress (2010 - 2025)
Gilead Sciences posted quarterly Construction in Progress of $745.0 million for Q4 2025, up 48.7% year-on-year from $501.0 million in Q4 2024, and up 48.7% on a QoQ basis from $501.0 million in Q4 2024.
Gilead Sciences (GILD) has 16 years of Construction in Progress data on file, last reported at $745.0 million in Q4 2025.
- For the quarter ending Q4 2025, Construction in Progress rose 48.7% year-over-year to $745.0 million; the trailing twelve-month figure through Dec 2025 stood at $745.0 million (up 48.7% YoY), and the FY2025 full-year result was $745.0 million, up 48.7% from the prior year.
- Construction in Progress for Q4 2025 stood at $745.0 million, up from $501.0 million in the prior quarter.
- Across five years, Construction in Progress topped out at $1.1 billion in Q4 2021 and bottomed at $501.0 million in Q4 2024.
- The 5-year median for Construction in Progress is $719.0 million (2022), against an average of $736.6 million.
- The widest annual swing landed in 2022, when Construction in Progress sank 31.98%; it then jumped 48.7% in 2025.
- A 5-year view of Construction in Progress shows it stood at $1.1 billion in 2021, then tumbled by 31.98% to $719.0 million in 2022, then decreased by 8.07% to $661.0 million in 2023, then decreased by 24.21% to $501.0 million in 2024, then surged by 48.7% to $745.0 million in 2025.
- The last three Construction in Progress figures came in at $745.0 million (Q4 2025), $501.0 million (Q4 2024), and $661.0 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 745.00 Mn |
| Dec 31, 2024 | 501.00 Mn |
| Dec 31, 2023 | 661.00 Mn |
| Dec 31, 2022 | 719.00 Mn |
| Dec 31, 2021 | 1.06 Bn |
| Dec 31, 2020 | 856.00 Mn |
| Dec 31, 2019 | 723.00 Mn |
| Dec 31, 2018 | 1.19 Bn |
| Dec 31, 2017 | 690.00 Mn |
| Dec 31, 2016 | 641.00 Mn |
| Dec 31, 2015 | 554.00 Mn |
| Dec 31, 2014 | 411.00 Mn |
| Dec 31, 2013 | 129.00 Mn |
| Dec 31, 2012 | 216.43 Mn |
| Dec 31, 2011 | 60.75 Mn |
| Dec 31, 2010 | 82.33 Mn |